Preklinisk forskning och läkemedelsutveckling
Hedenstierna laboratory (large animal facility)
Advanced local large animal research infrastructure. Performs surgery and examinations of respiratory, circulatory, cerebral and renal physiology and pathophysiology.
Center for Animal Research (CFV-UU)
A local infrastructure with animal storage in accordance with rules and regulations.
Uppsala University Behavioral Facility (UUBF)
A local infrastructure for neurology related behavioral research.
Biosafety Level 3 Lab (BSL3 lab)
A local infrastructure. One of few in Sweden, used for different types of pathogens.
UU-SLU Collaborative Platform (U-Share)
A collaborative translational research facility combining research on human and animal disease development.
Excellence Of Diabetes Research in Sweden (EXODIAB)
A national infrastructure providing a platform for diabetes research.
A national infrastructure providing a platform for stem cell research.
Genome Engineering Zebrafish
A national infrastructure of advanced animal research methods.
Human glioblastoma cell culture (HGCC) resource
A local infrastructure of well-characterized glioblastoma cell lines from surgical patient samples.
Clinical Diabetes and Metabolism Laboratory
A local infrastructure with a clinical and experimental research laboratory for diabetes and metabolism.
Drug Discovery and Development Platform (DDD)
A national industry-standard infrastructure for academic drug discovery.
Chemical Biology Consortium Sweden (CBCS)
A national infrastructure for the discovery, development and utilisation of small molecules and chemical tools. The Uppsala node performs large-scale phenotypic screening of cell models.
TestaCenter (testbed for biological production)
A collaborative infrastructure and unique test bed and innovation centre for bioprocess technologies. Founded by Cytiva and Uppsala University.
SweDeliver, the Swedish Drug Delivery Center
A collaborative infrastructure support focusing on drug delivery via parenteral, oral and pulmonary administration.
European Gram Negative AntiBacterial Engine – 2 (ENABLE)
IMI-funded international platform for the development of new antibiotics. ENABLE is the engine for European antibacterial drug discovery.
To reach a deeper understanding of pathogenic mechanisms, basic experimental research infrastructures, consisting of small and large animal facilities, human tissues and cells, and modern advanced technologies (for example, CRISPR gRNA activity and genotyping optimisation, simple and multiplex CRISPR/Cas9 genome modification, support for site-specific DNA insertion, phenotyping by fluorescent PCR, automated cell imaging system), will be provided.
Researchers are therefore supported by facilities for animal model research, with mice and zebrafish as the principal model organisms. UUBF provides a platform for behavioural testing of mice, rats and fish. The Hedenstierna Laboratory is a core facility with large animals (pigs) for translational surgery, transplantation, respiratory research and imaging.
In vivo facilities also include collaboration between Uppsala University and the Swedish University of Agricultural Sciences in Uppsala. A security laboratory for the study of BSL3 organisms, for example zoonotic viruses and human pathogens, is available. The Clinical Diabetes and Metabolism Laboratory has an established clinical research unit combining PET/MR imaging protocols with hyperinsulinemic-euglycemic clamp and a laboratory for experimental work in cell and molecular biology.
Human tissues and cells, as well as pathogens, can be evaluated using in vitro model systems. Cell cultures established from patient tissue are "living samples" of that individual. Examples of analyses include knockdown of a specific gene in human cells with CRISPR/Cas9 gene editing and phenotypic characterisation, including metabolism, immunohistochemistry and automated cell imaging.
The HGCC resource contains well-characterised brain tumour stem cells derived from patients and accompanying clinical data available as an open resource. Other examples of newly developed technologies based on patient tissue are organoid cultures, which can be used for mechanistic studies or drug discovery.
Drug development, involving human data and clinical samples, is an integral part of a translational research process towards precision medicine that necessitates support from different types of research infrastructures.
Uppsala University hosts the only faculty of pharmacy in Sweden. It has a close collaboration with SciLifeLab and the pharmaceutical industry. The Testa Center, in collaboration with Cytiva, is a test bed for drug production and bioprocessing. SweDeliver provides expertise in drug delivery, focusing on new strategies for parenteral, oral and pulmonary drug delivery.
The Drug Discovery and Development (DDD) platform offers integrated drug discovery efforts, including expertise and strategic support for technology development or to help progress projects towards preclinical proof-of-concept. DDD works on small molecules, human antibodies and new modality therapies.
Antibiotic resistance is a huge global threat to health. Despite the great need for new antimicrobials, very few new, effective antibiotics have been brought to market in the last decades. The ENABLE project under the Innovative Medicines Initiative (IMI) New Drugs for Bad Bugs (ND4BB) programme is working to advance the development of potential antibiotics against Gram-negative bacteria. ENABLE, and its successor COMBINE, are led by Uppsala University.
COMBINE is a European collaboration in which eleven partners from academia and the pharmaceutical industry are paving the way for more efficient development of new antibiotics.
ReAct is a global network dedicated to the problem of antibiotic resistance and infrastructure, providing services and advice on how to design research for infection prevention and lessen the burden of antibiotic resistance.
The Uppsala Antibiotic Center provides training and research design support for novel approaches in all scientific disciplines, including new antibiotics, better understanding of resistance development, faster diagnostic methods, new economic models for drug development, global governance and better understanding of how to change behaviour around antibiotic use and the spread of pathogenic bacteria.